DATA Globaldata Plc

RNS Number:7010O
Provalis PLC
14 December 2001


For Immediate Release
14th December 2001



               PROVALIS ANNOUNCES INTENTION TO FOCUS ON LONDON
                   AND NASDAQ LISTINGS AND TO DE-LIST FROM
                        THE AUSTRALIAN STOCK EXCHANGE


Provalis plc, the integrated healthcare company with listings on the London
Stock Exchange ("LSE") and NASDAQ, and also on the Australian Stock Exchange
("ASX"), today announces that it will de-list from the ASX on 14th June 2002.
Provalis shares will, of course, continue to have listings on both the LSE and
on NASDAQ.

Provalis originally listed on the ASX in 1986, at which time the Company's
operations were mainly based in Australia. In 1994, Provalis obtained a
secondary listing on the LSE, and then followed this by converting the LSE
listing to its primary listing in 1997, with the listing on the ASX becoming
secondary.

The decision to de-list from the ASX has been taken for the following reasons:-

There have been prolonged low levels of trading volume and activity in
Provalis shares on the ASX. Turnover of Provalis shares in the 12 months to
30th June 2001 was only 1.7% of the turnover on the LSE.

Provalis' Australian operations have effectively ceased, and its remaining
Australian based assets make up only 2% of its total assets as at 30th June
2001.

As at 30th June 2001, the number of Provalis shares registered on its
Australian register comprised only 1.8% of Provalis' total share capital.

The ASX has recently announced changes to its listing rules requiring "foreign
entities" such as Provalis to apply for a primary listing on the ASX, or be
de-listed from 30th June 2002. The costs to Provalis of maintaining a primary
listing on the ASX, in addition to the primary listing on the LSE, outweigh
any benefits.

Those shareholders on Provalis' Australian register will need to be issued
with UK share certificates by the time of de-listing.  Those shareholders
affected will be receiving further details directly from the Company.

Phil Gould, CEO of Provalis, said "Provalis had its origins in Australia but
is now a broad healthcare business centred in the UK, and operating globally.
This is reflected in our institutional and private shareholder base. It was a
difficult decision for us to decide to de-list from the Australian Stock
Exchange. However, in view of the number of Provalis shares on our Australian
register, and the level of trading activity involving those shares, the costs
to Provalis, in both financial terms and also management time, outweigh the
benefits of maintaining this listing."


Provalis' Internet Website ; http://www.provalis.com

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act
of 1995: Statements in this announcement that relate to future plans,
expectations, events, performances and the like are forward-looking statements
as defined in the US Private Securities Litigation Reform Act of 1995. Actual
results of events could differ materially from those described in the
forward-looking statements due to a variety of factors.  Such factors include,
among others: the success of the Group's research and development strategy;
uncertainties related to future trial results and the regulatory process; the
execution and success of collaborative agreements with third parties; the
impact of future laws, regulations and policies; the Group's intellectual
property position and the success of patent applications for its products and
technologies; stock market trends in the Group's sector; the Group's
dependence on key personnel; general business and economic conditions; and
other factors beyond the Group's control that may cause the Group's available
capital resources to be used more quickly than expected.  These and other
factors that could affect the Company's future results are more fully
described in its filings with the US Securities and Exchange Commission, in
particular the latest 20-F filing, copies of which are available from the
Company Secretary at the Company's registered address.



For further information:-

Dr Phil Gould, Provalis plc,  Tel:  01244 833463
Mr Lee Greenbury, Provalis plc,  Tel:  01244 833402
Lisa Baderoon, Buchanan Communications,  Tel:  020 7466 5000


Notes to Editors


Provalis plc (LSE.PRO and NASDAQ.PVLS) is an integrated healthcare company
with three separate divisions:-

Healthcare - This division sells and markets branded, third party,
prescription medicines in the UK to GPs and hospitals through its own
regionally managed sales force.  This division sells products in the areas of
muscular-skeletal disorders, gastroenterology, osteoporosis, migraine and
dermatology.

Medical Diagnostics - This division develops and sells medical diagnostic
products to world markets through distributors.  The division has an
established business in diagnostic products for infectious diseases and has
recently launched the innovative products GlycosalTM and OsteosalTM in the
areas of diabetes and osteoporosis respectively.

Therapeutics R&D - This division develops a range of vaccine candidates for
infectious diseases through a network of research collaborators.

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024